The global market for Antihyperlipidemic Drugs Market was estimated to be worth USD 13.49 billion in 2023 and is expected to grow to USD 25.65 billion by the end of 2032, according to a report released by Zion Market Research. Over the course of the projection period, the market is anticipated to rise at a CAGR of 7.4%. The growth factors, barriers, and effects on demand for the worldwide antihyperlipidemic drug market are examined in this study for the period of forecasting. Additionally, it will support you as you navigate and investigate the new potential in the antihyperlipidemic drug sector.

Global Antihyperlipidemic Drugs Market: Overview

Hyperlipoproteinemia, another name for hyperlipidemia, is a lipid disorder marked by high blood levels of fat (lipid). It is brought on by issues with plasma lipoprotein synthesis and degradation, plasma lipid transport, or lipid metabolism. Treating hyperlipidemia is necessary because it is a dangerous medical condition.

Triglycerides and cholesterol are examples of chemical compounds known as lipids that are insoluble in water. A medical disorder called hyperlipidemia is characterized by an increase in blood lipid levels. This increase in cholesterol levels causes fatty deposits to accumulate in the arteries, which clog the patient’s arteries.

The obstructions may thereby increase the risk of heart attacks. As a result, hyperlipidemia is a serious illness that needs to be treated. Medications classified as lipid-lowering, cholesterol-lowering, or antihyperlipidemic medicines are used to treat excessive blood levels of fats and lipoproteins, which are fats that contain protein. These drugs are intended to lower the risk of heart attacks and treat cardiovascular conditions like atherosclerosis.

https://medium.com/@samruddhihatekar2004/antihyperlipidemic-drugs-market-size-share-trends-growth-and-forecast-2032-59ef24d21e54

Global Antihyperlipidemic Drugs Market: Growth Factors

The market for antihyperlipidemic medications is expanding quickly worldwide. The primary driver of the market’s expansion is the increase in hyperlipidemia and cardiovascular disease cases. The main cause of death worldwide is CVD. Cardiovascular disease (CVD) claimed 17.9 million lives in 2019; this accounted for 32% of all fatalities globally. 85 percent of these deaths were caused by heart attacks and strokes. Additionally, cardiovascular disease (CVD) is the leading cause of death in Europe, accounting for 47% of deaths in women and 39% in men.

The rise in sedentary lifestyles is one of the factors driving the market’s expansion. Additionally, an increase in the prevalence of conditions linked to uneven blood cholesterol levels supports the expansion of the antihyperlipidemic medication market. Further driving the market’s expansion is the increased public awareness of the problems associated with hyperlipidemia.

Patients with COVID-19 frequently experience cardiovascular issues, which when combined with pre-existing cardiovascular comorbidities and RF, can have a serious negative impact on clinical outcomes or even result in death. This link should be known by clinicians worldwide so they can recognize patients who are more vulnerable.

Global Antihyperlipidemic Drugs Market: Segmentation

Based on the route of administration, drug class, distribution channel, and geography, there are two segments in the global market for antihyperlipidemic medications.

The intravenous and oral segments of the global market are separated based on the mode of administration.

The family of medications known as antihyperlipidemic medicines includes fibric acid derivatives, combinations, PCSK9 inhibitors, statins, bile acid sequestrants, and inhibitors of cholesterol absorption.

Owing to the rise in the prevalence of cardiovascular diseases, statins held the biggest market share among antihyperlipidemic medications in 2018. Moreover, statins lower the risk of heart attacks, which is another important aspect driving the market’s expansion.

To offer a thorough analysis of the market, the market size for antihyperlipidemic medications is examined based on segments, drug class, and geographic location.

The market is segmented into several medication classes, including fibric acid derivatives, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and statins.

Global Antihyperlipidemic Drugs Market: Regional Analysis

Over the projected period, North America is predicted to maintain its leading position in the global market for antihyperlipidemic medications in terms of revenue. Given the rise in vascular illnesses and amputations in North America, it is anticipated that the market for antihyperlipidemic medications will expand. The growth of the North American market can also be attributed to the large R&D and healthcare spending that local governments and commercial prosthetics businesses have made.

Due to easy access to antihyperlipidemic medications, North America held the largest market share for these medications in 2018. This trend is anticipated to continue. The rise in sedentary lifestyles in the area is also a significant component of the market’s expansion. The market for antihyperlipidemic medications is also growing as a result of the rise in the obese population.

Europe is anticipated to occupy the second position in the market with respect to market share for antihyperlipidemic medications. This is because countries like France and Germany require people to have health insurance, and there is a lot of disposable cash in the region’s healthcare sector as well as a lot of R&D going on.

Antihyperlipidemic Drugs Market

Global Antihyperlipidemic Drugs Market: Competitive Players

  • Biotest AG
  • Shire Plc
  • Pfizer, Inc.
  • Grifols S.A.
  • AstraZeneca plc
  • Talecris Biotherapeutics, Inc
  • Baxalta Incorporated
  • Kedrion S.p.A.
  • Octapharma AG
  • Boehringer Ingelheim GmbH

are the dominant players that are functioning in the global antihyperlipidemic drug market.

The Global Antihyperlipidemic Drugs Market is segmented as follows:

By administration

  • intravenous
  • oral

By drug class

  • Cholesterol absorption inhibitors
  • bile acid sequestrants
  • statins
  • combination
  • PCSK9 inhibitors
  • fibric acid derivatives

By distribution channel

  • online retailers
  • retail stores
  • hospital pharmacies

Global Antihyperlipidemic Drugs Market: Regional Segment Analysis

  • North America
  • The U.S.
  • Canada
  • Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Anti-hyperlipidemic medication use has increased significantly as a result of the rise in sedentary behavior. Additionally, an increase in the prevalence of conditions linked to uneven blood cholesterol levels is a factor driving the expansion of the anti-hyperlipidemic drug market. Further driving the market’s expansion is the increased public awareness of the problems associated with hyperlipidemia.

Contact Us:
Zion Market Research
USA/Canada Toll Free: 1 (855) 465-4651
Newark: 1 (302) 444–0166
Web: https://www.zionmarketresearch.com/
Blog: https://zmrblog.com/